HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M Eugenia Socías Selected Research

Opioid-Related Disorders (Opiate Addiction)

5/2024Characterising methamphetamine/amphetamine use among opioid agonist therapy-seeking adults with prescription-type opioid use disorder in Canada.
1/2024The FASTER-BUP Study, Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose: Protocol for an Observational Prospective Study.
11/2023Evaluation of audit and feedback to family physicians on prescribing of opioid analgesics to opioid-naïve patients: A pragmatic randomized delay trial.
1/2023The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs.
1/2022Opioid agonist treatment improves progression through the HIV cascade of care among people living with HIV who use unregulated opioids.
1/2021Trajectories of Retention in Opioid Agonist Therapy and Overdose Risk During a Community-Wide Overdose Epidemic in a Canadian Setting.
1/2020Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada.
1/2020Trajectories of retention in opioid agonist therapy in a Canadian setting.
1/2019Slow release oral morphine versus methadone for the treatment of opioid use disorder.
1/2018Evaluating Slow-Release Oral Morphine to Narrow the Treatment Gap for Opioid Use Disorders.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M Eugenia Socías Research Topics

Disease

11Opioid-Related Disorders (Opiate Addiction)
05/2024 - 12/2016
3Pain (Aches)
11/2023 - 01/2020
2Chronic Pain
11/2023 - 01/2021
2Opiate Overdose
01/2021 - 01/2021
2Hepatitis C
01/2019 - 11/2015
2HIV Infections (HIV Infection)
01/2019 - 09/2017
1Frailty
01/2023
1COVID-19
12/2020
1Nausea
01/2020
1Sleep Initiation and Maintenance Disorders (Insomnia)
01/2020
1Infections
01/2019
1Sexually Transmitted Diseases (Sexually Transmitted Disease)
06/2017
1Disease Progression
08/2011

Drug/Important Bio-Agent (IBA)

7Opioid Analgesics (Opioids)IBA
05/2024 - 12/2016
5Methadone (Dolophine)FDA LinkGeneric
05/2024 - 01/2019
2Naloxone Drug Combination BuprenorphineFDA Link
05/2024 - 01/2020
2Buprenorphine (Subutex)FDA LinkGeneric
01/2024 - 01/2020
2Fentanyl (Sublimaze)FDA LinkGeneric
01/2024 - 01/2021
22-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA
01/2023 - 01/2023
2Illicit Drugs (Recreational Drugs)IBA
11/2021 - 12/2020
2Morphine (MS Contin)FDA LinkGeneric
01/2019 - 01/2018
1Amphetamine (Amfetamine)FDA LinkGeneric
05/2024
1Methamphetamine (Desoxyn)FDA LinkGeneric
05/2024
1Therapeutic UsesIBA
01/2020
1InterferonsIBA
01/2019
1Antiviral Agents (Antivirals)IBA
01/2019
1Reverse Transcriptase InhibitorsIBA
09/2017
1N,N-dimethyl-4-anisidine (DMPA)IBA
06/2017

Therapy/Procedure

5Therapeutics
05/2024 - 12/2016
2Injections
01/2024 - 01/2021
1Time-to-Treatment
01/2023
1Retention in Care
01/2021
1Pain Management
01/2020
1Continuity of Patient Care
11/2015
1Highly Active Antiretroviral Therapy (HAART)
08/2011